Iksuda Therapeutics announces first patient successfully dosed in phase 1 trial evaluating IKS03 in advanced B cell non-Hodgkin lymphomas

Contributed by: Business Wire

Tags

Science
Other Science
Biotechnology
Research
Pharmaceutical
Oncology
Health
FDA
IKS03

More Like This

Iksuda Therapeutics announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2

Iksuda to Present IKS014 Phase 1 Data at ESMO

Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO

Iksuda Therapeutics Receives FDA IND Clearance for IKS014

Iksuda to Present Preliminary Analysis of Oesophageal Cancer Data From Phase 1 study of IKS014 at ASCO Gastrointestinal Cancer Symposium

Iksuda to Present Growing ADC Pipeline at AACR

PR Newswire associated0

Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates

Business Wire logo

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD